Sempra's Q3 Earnings Outpace Estimates, Revenues Increase Y/Y

Sempra’s Q3 2026 adjusted EPS rose 26.1% year over year to $1.40, beating the $1.20 consensus by 16.7%, while revenue increased 1.3% to $3.19 billion but missed estimates by 4.8%. Texas Utilities earnings rose to $460 million from $306 million, supported by higher Oncor equity earnings; Oncor’s peak demand reached a record 33.3 GW. Sempra raised 2026 GAAP EPS guidance to $7.41–$8.41, maintained 2027 guidance of $5.10–$5.70 and its 7–9% long-term EPS growth target, while projecting 2026 adjusted EPS of $4.80–$5.30.

Analysis

The earnings signal is more valuable as evidence of a Texas regulated-load and rate-base cycle than as a broad beat: incremental demand can support wires investment and future allowed earnings, but it does not automatically translate into near-term margin expansion. For Sempra, the key transmission is whether load growth converts into approved capital additions and timely cost recovery; higher depreciation, operating costs and interest expense already absorb part of the benefit. Import Path 1 approvals are therefore a catalyst only if they survive rehearing and appeals and progress into funded construction.

Over the next 1–3 months, the market may reward continued Oncor demand and regulatory execution, while scrutinizing the divergence between adjusted and GAAP guidance and the quality of the raised GAAP outlook. Over 6–18 months, the upside case depends on rate-base growth outpacing financing and operating costs. Rising debt alongside minimal reported cash warrants monitoring, but operating cash generation improved; the snapshot alone does not establish a liquidity problem. A reversal would be weaker ERCOT load, delayed cost recovery, adverse regulatory rulings, or financing costs outrunning returns.

Contrarian point: record peak demand is a compelling structural narrative, but peak load is not equivalent to annual energy sales or earnings. The more important variable is approved, recoverable investment—not the demand record itself. No valuation or post-earnings price data are supplied, so the beat alone is insufficient to establish attractive entry or a mispriced move.

Key Decisions for Investors

• Do not chase SRE solely on the EPS surprise. Treat the report as a constructive fundamental update, but require the share-price reaction and valuation context before adding exposure.
• Set an SRE watch for Oncor load trends, capital-plan additions, and Import Path 1 rehearing or appeal outcomes. A clearer long thesis requires evidence that investment is approved and recoverable, not just rising peak demand.
• If seeking a relative expression, consider a modest SRE-versus-XLU long only after confirming SRE has not already rerated; the thesis is Texas rate-base growth, while the main risks are regulatory delay and financing-cost pressure. Exit or reassess if approvals are materially delayed or company guidance weakens.
• Monitor debt and financing costs against operating cash generation and the adjusted-versus-GAAP guidance bridge. A deterioration in cash conversion or evidence that incremental interest and depreciation consume rate-base gains would falsify the constructive view.